We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+50.47%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$244M
Cap. Flow
+$79.7M
Cap. Flow %
14.07%
Top 10 Hldgs %
52.72%
Holding
83
New
26
Increased
22
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$10.7M
2
SNY icon
Sanofi
SNY
+$9.45M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$9.01M
4
PNTG icon
Pennant Group
PNTG
+$8.5M
5
MDCO
Medicines Co
MDCO
+$7.63M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$7.86M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.4M
3
ZGNX
Zogenix, Inc.
ZGNX
+$6.78M
4
DXCM icon
DexCom
DXCM
+$6.17M
5
ABMD
Abiomed Inc
ABMD
+$5.33M

Sector Composition

Rank Sector Weight
1 Healthcare 82.4%
2 Miscellaneous 13.14%
3 Real Estate 1.69%
4 Communication Services 1.29%
5 Industrials 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
76
Savara
SVRA
$1.08B
– –
-316,679
Closed -$839K
LUMO
77
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-30,331
Closed -$434K
IVC
78
DELISTED
Invacare Corporation
IVC
– –
-129,361
Closed -$970K
TCDA
79
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-65,568
Closed -$2.02M
ABMD
80
DELISTED
Abiomed Inc
ABMD
– –
-29,950
Closed -$5.33M
AIMT
81
CALL
DELISTED
Aimmune Therapeutics
AIMT
– –
-9,100
Closed -$191K
AIMT
82
PUT
DELISTED
Aimmune Therapeutics
AIMT
– –
-10,000
Closed -$209K
ARQL
83
DELISTED
Arqule Inc
ARQL
– –
-412,388
Closed -$2.96M
1 2 3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Eversept Partners held 83 positions worth $566M, up 76% from $322M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Eversept Partners deployed $79.7M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Amarin Corp, an estimated $7.86M trimmed.

  • Eversept Partners's largest Q4 2019 buy was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
  • Eversept Partners added most to BioCryst Pharmaceuticals in Q4 2019, an estimated $10.7M increase.
  • Eversept Partners's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $7.86M.
  • Eversept Partners fully exited Alnylam Pharmaceuticals in Q4 2019, selling an estimated $7.4M.
  • Eversept Partners's ten largest holdings make up 53% of its $566M portfolio in Q4 2019.
  • Eversept Partners opened 26 new positions and closed 11 in Q4 2019.
  • Eversept Partners's portfolio value rose 76% quarter-over-quarter to $566M.

Based on Eversept Partners's 13F filing for Q4 2019, filed 13 Feb 2020.